Quetiapine fumarate (Seroquel | is a dibenzothiazepine psychotropic agent that was introduced in 1997 for treating psychoses. Quetiapine is being found with increasing frequency in postmortem cases in Virginia. We report the postmortem results and histories of 20 quetiapine cases from the Office of the Chief Medical Examiner in Virginia covering the period 1999 through 2004. Quetiapine was extracted from blood using a basic drug solid-phase extraction (SPE) and identified by full scan electron impact gas chromatography-mass spectrometry (GC-MS). Quetiapine quantification was accomplished by forming the trimethylsilyl derivative with bis(trimethylsilyl)trifluoracetamide/trimethylchlorosilane and using selected ion monitoring GC-MS. The quetiapine trimethylsilyl derivative ions acquired were m/z 210, 239, and 322. Methapyrilene was the internal standard, and ions m/z 97 and 58 were monitored. The method was linear from 0.1 to 5.0 mg/t with a limit of quantitation of 0.1 mg/L. The quetiapine mean and range of concentrations found in each tissue are as follows: peripheral blood, 7.7 mg/L (0.14-37 mg/L, n = 17); heart blood, 23.63 mg/L (0.53-76 rag/L, n = 4); liver, 91 mg/Kg (1.1-510 mg/Kg, n = 19); bile, 44 mg/L (6.0-96 mg/L, n = 4); urine, 15 mg/L (1.9-37 rag/L, n = 8); gastric, 897 mg total (3.5-3960 rag, n = 7); and vitreous, 1.4 mg/L (0.2-3.2 rag/L, n = 5). The average of all blood concentrations in 18 cases in which quetiapine contributed to the cause of death was 7.95 mg/L (0.4-76 rag/L). The manner of death in 13 of those cases was suicide, two were undetermined, and three were accidents. In two cases in which quetiapine was an incidental finding, the blood concentrations were 0.14 and 1.0 mg/L. Quetiapine and other toxicological findings are presented with the cause and manner of death to assist in interpreting future quetiapine findings in postmortem samples. The dibenzothiazepine drug, quetiapine fumarate (Seroquel| was approved in 1997 by the U.S. Food and Drug Administration for the treatment of psychotic disorders and has been shown to be successful in treating both negative (e.g., social withdrawal) and positive (e.g., hallucinations) symptoms of schizophrenia (1,2). The structure of quetiapine (Figure 1 
The dibenzothiazepine drug, quetiapine fumarate (Seroquel| was approved in 1997 by the U.S. Food and Drug Administration for the treatment of psychotic disorders and has been shown to be successful in treating both negative (e.g., social withdrawal) and positive (e.g., hallucinations) symptoms of schizophrenia (1, 2) . The structure of quetiapine ( Figure 1 ), 2-[2-(4-dibenzo [b,f] [1, 4] thiazepin-11-yl-1-piperazinyl)ethoxy]-ethanol, is structurally similar to the prototype atypical antipsychotic, clozapine (3) . Quetiapine fumarate is dispensed as 25-, 100-, 200-, and 300-rag tablets with daily doses ranging from 150 to 750 mg and 400 to 800 mg for treating schizophrenia and bipolar disorder, respectively (3) . Quetiapine is an antagonist at the serotonin 5HT1A and 5HT2 receptors, dopamine D1 and D2 receptors, histamine H1 receptor, and the adrenergic @1 and ~2 receptors (3, 4) . Binding at both serotonin and dopamine receptors accounts for quetiapine's antipsychotic effects. The adverse effects of quetiapine are thought to be in part related to its affinity for the H1 and the (~1 receptors (5) . H1 receptor binding contributes to the somnolence produced by quetiapine (6, 7) , and blockade at the ~1 receptor is related to the cardiovascular side effects (7, 8) .
Quetiapine is 83% bound to plasma proteins, has a Vd 10 L/kg, and is rapidly absorbed from the gastrointestinal track, Coronary artery disease, hypertensive heart disease, old myocardial infarct, pulmonary edema, and visceral congestion
Foam exuding from the nose and mouth, Lungs and liver congested, enlarged heart, atherosclerosis of coronary arteries.
Mild decomposition, pulmonary and visceral congestion, cerebral edema, bilateral hippocampi sclerosis.
Congestion of lungs and liver, atherosclerosis of the aorta, adhesions of the left lung peaking at 1.5 h (3). The half-life of quetiapine has been estimated to be 6 h within the clinical dose range proposed, and in a non-fatal overdose, the half-life has been estimated to be longer (7, 9) . Quetiapine is primarily metabolized in the liver by the cytochrome ,~ 3A4 isoenzyme and is excreted primarily in the urine (3). Several quetiapine metabolites have been identified with only the 7-hydroxy and the 7-hydroxy-N-dealkylated metabolites retaining any activity (10, 11) . Phenytoin, an inducer of the cytochrome P450 enzyme, has been shown to increase quetiapine's metabolism fivefold (12) . There are several quetiapine non-fatal overdoses reported in the literature. The clinical presentation of the individual typically includes tachycardia, loss of consciousness, hypotension, and the need for airway maintenance. Harmon et al. (6) reported a 26-year-old female with a history of paranoid schizophrenia who overdosed on 1130 tablets of quetiapine (200 mg). The individual lost consciousness at approximately 2.5 h, required airway management, and presented with persistent tachycardia (6). Hustey (13) reported a D-year-old male who ingested 9600 mg of quetiapine: he became unresponsive in 1 h; presented with mild hypokalemia (3.3 meq/L), elevated glucose (137 mg/dL), prolonged QTc interval, hypotension, and tachycardia; and needed airway protection. He was not alert until 41 h later before being able to follow commands (13) . Others have also reported hypokalaemia and first-degree heart block with ingestion of 9600 mg of quetiapine (3, 11) . Nudelman et al. (9) reported a 21-year-old male with schizoaffective disorder who was brought to an emergency room following a suicide attempt with 4700 mg of quetiapine and 600 mg of fluoxetine. The individual became drowsy and disoriented and had an elevated heart rate that persisted for 48 h after ingestion. There were no conduction abnormalities, change in blood pressure, respiratory depression, or abnormal blood chemistries. The individual's plasma quetiapine concentration 60 h post ingestion was 0.18 mg/L (9). Pollak and Zbuk (7) reported a 40-year-old female with a psychiatric history who ingested 3000 mg of quetiapine fumarate and was brought to an emergency room shortly thereafter. She presented with hypotension and tachycardia. She became obtunded 90 rain after arriving at the emergency room, at which time her serum quetiapine concentration was 1.8 mg/L. Serum quetiapine concentration was 0.18 mg/L 22 h after the overdose, with her blood pressure returning to normal, although tachycardia persisted for 42 h (7).
There are a few quetiapine postmortem tissue distribution cases presented in the literature. Anderson and Fritz reported quetiapine postmortem distribution in seven cases (14) . They reported heart blood quetiapine concentrations from present less than 0.10 mg/L to as high as 49 mg/L. Four cases, where the manner of death was suicide, had heart blood concentrations averaging 14. Fernandes and Marcil (17) reported an overdose in which a 52-year-old male ingested an estimated 10,800 mg of quetiapine. Resuscitation efforts were unsuccessful, and his serum quetiapine concentration was 18.3 mg/L. Autopsy revealed quetiapine pill fragments in the gastric content, cardiomegaly, left ventricular hypertrophy, pulmonary congestion, and a negative immunoassay screen for the deceased's other medication (17) .
In Virginia, the Medical Examiner's office has seen an increase in quetiapine findings in postmortem blood. Therapeutic quetiapine concentrations range from 0.19 to 0.63 mg/L for a 150 mg dose taken three times a day chronically and 0.14 to 0.36 mg/L for a single 75-mg dose, with toxicity reported at 13 mg/L (18, 19) . A majority of the cases reported here contain quetiapine blood concentrations well above therapeutic concentrations reported in the literature. This combined with an increase in quetiapine prescriptions warranted an investigation into the tissue distribution of quetiapine (11) . The quetiapine tissue distribution from 20 cases between the years 1999 and 2004 from the Medical Examiner's office in Virginia is presented in Table I . The case histories are presented in Table II .
Experimental
Quetiapine fumarate was obtained from AstraZeneca. Methapyrilene and bis(trimethylsilyl)trifluoracetamide (BSTFA) containing t% trimethylchlorosilane (TMCS) were purchased from Alltech and Pierce, respectively. Varian Bond Elute Certify II solid-phase columns were obtained from Varian (Walnut Creek, CA). All other chemicals and reagents were A.C.S. reagent grade or better and purchased from various vendors. Samples were collected at the time of postmortem examination and kept refrigerated until analyzed. Calibrators and controls were prepared by adding quetiapine from a methanolic standard to whole blood. Specimens were diluted with distilled water to ensure quantitation within the limits of linearity, 0.1-5.0 mg/L. Methapyrilene was chosen as an internal standard for quantitating underivatized quetiapine with other alkaline extractable drugs. However, underivatized quetiapine chromatographs poorly, producing broad tailing peaks. Derivatizing quetiapine with BSTFA eliminated the undesirable broad peaks and still allowed for the simultaneous analysis of quetiapine and other alkaline extractable drugs. Although methapyrilene is not derivatized with BSTFA, the results from using methapyrilene were acceptable, and, therefore, a different internal standard has not been fully investigated.
Quetiapine confirmation and quantitation
A 1-mL methanolic solution of the internal standard methapyrilene (1 lJg/mL) was added to l-mL aliquots of calibrators, controls, and samples followed by 4 mL of acetonitrile. The mixture was rotated for 5 rain, centrifuged for 5 min at 2500 rpm, and then the supernatant was transferred to a test tube. The supernatant was evaporated under a stream of nitrogen to approximately 1 mL and added directly to a solidphase column prepped with 2 mL MeOH followed by 2 mL of 1M phosphate buffer (pH 6). The column was washed with I mL 0.1M aqueous acetic acid, dried under vacuum, rinsed with 6 mL MeOH, and then dried once more. Quetiapine was eluted with 2 mL of ethyl acetate/ammonium hydroxide mixture (98:2) and collected in a conical shaped test tube. The sample was dried under nitrogen at 35~ BSTFA (0.05 mL) containing 1% TMCS was added, and the test tube was capped and incubated at 90~ for 30 min. The sample was transferred to a conical shape GC vial, and 1 IJL was injected for quantitation.
Instrument parameters
Quantitation was performed using an HP model 5890 GC with a 5972 HP mass selective detector (MSD) and HP 7673 auto sampler. The inlet temperature was set a 270~ with an injection volume of I pL. An HP-5MS capillary column (30 m • 0.25-ram i.d., 0.25-pro film thickness), from Agilent, was used for separating the analytes. The oven temperature was programmed from 140~ to 300~ at 30~ with the initial and final temperature held for 0 and 7.17 min, respectively, giving a total run time of 12.5 rain. Constant flow mode was selected using helium as the carrier gas with a flow rate of 1.0 mL/min. The MSD was operated in the electron impact mode (70 eV) with autotune conditions. The auxiliary transfer line temperature was maintained at 280~ Selective ion monitoring was used to monitor ions m/z 210, 239, and 322 for quetiapine and m/z 58, 97 for methapyrilene, with quantitation ions shown in bold face.
Results
The method was linear for quantitating the quetiapine trimethylsilyl derivative between 5.0 to 0.1 rag/L, with 0.1 and 0.05 mg/L being the limit of quantitation and detection, respectively. The presence of underivatized quetiapine in whole blood was confirmed by full scan electron ionization GC-MSD using a liquid-liquid extraction described elsewhere (20) . The postmortem tissue distribution of quetiapine from the 20 cases analyzed is listed in Table I . Postmortem samples examined by the Medical Examiner's Office included heart blood (n = 4), peripheral blood (n = 17), liver (n = 20), antemortem blood (n = 2), bile (n = 4), urine (n = 8), vitreous fluid (n = 6), and gastric (n = 14). Peripheral blood and liver were submitted for analysis more often than any other sample. The average of all peripheral postmortem blood quetiapine concentrations for Virginia was 7.7 mg/L (range: 0.14-37 rag/L). The average of all postmortem liver quetiapine concentrations for Virginia cases excluding case 11 was 90.9 mg/kg (range: 1.1-510 mg/kg). Drugs found in combination with quetiapine included antihistamines, anticonvulsants, analgesics, anxiolytics, antidepressants, and ethanol and are listed in Table I . The concentrations of the other drugs in a majority of the cases were quantitated in various tissues (findings not presented) as well. Based on the concentration of quetiapine and the other drugs, the most frequent cause and manner of death was multiple drug intoxication and suicide, respectively. Antemortem serum and blood were obtained from case 9 and gave a quetiapine blood/serum ratio equal to 1:1. This result could not be validated by a literature search and should be interpreted as preliminary.
Discussion
In the cases examined by the Medical Examiner's office in Virginia, the average quetiapine concentration in blood in which quetiapine contributed to the cause of death (cases 1-9, 11-17, and 19 and 20) was 12.1 mg/L (range: 0.40-76 rag/L, n = 18). Liver concentrations are higher than blood concentrations and are consistent with the literature, demonstrating the large volume of distribution of quetiapine (14) . The average bile concentration from four of the Virginia cases was 44 mg/L (range: 6--96 rag/L). In those four cases, the bile concentration was 6 to 10 times higher than the peripheral blood quetiapine concentration. This finding is in agreement with Hoppenswasser et al. (16) , who reported bile concentrations to be 10-fold higher than the blood, and suggests accumulation in the bile to be the result of enterohepatic cycling of quetiapine.
Case 6 indicates postmortem redistribution with a heart and peripheral blood ratio of 2:1. The ratio of quetiapine in the heart and femoral blood indicates that postmortem distribution does occur and is in agreement with earlier findings reported by Jenkins et al. (14) and Anderson and Fritz (15) . Together they report five cases where heart and femoral blood was analyzed. Their data gives a combined average ratio of 2.5.
The average peripheral blood quetiapine concentration in which suicide was determined to be the manner of death was 10.97 mg/L (n = 11, range: 1-37 mg/L). Removing the two suicide cases, 7 and 9, in which the deceased was hospitalized prior to death raises the average peripheral blood concentration to 11.3 mg/L. Although these averages are well above quetiapine therapeutic concentrations, the cause of death was due to quetiapine and one or more drugs in all except cases number 9 and 20. In these two cases the cause of death was an acute quetiapine overdose. In case number 9, the ethanol concentration at the time of admission is not known, and the antemortem blood quetiapine concentration is 4 times more than the postmortem concentration. The postmortem blood quetiapine concentration in case 20 is more than 10 times the therapeutic concentration. However, other substances were found even though they were not considered to contribute to the cause of death. This makes determining a sole lethal postmortem blood concentration of quetiapine challenging when also taking into consideration a previously reported case in which a quetiapine blood concentration < 1 mg/L was reported as the cause of death (15) . mortem blood quetiapine concentrations are > 1 mg/L quetiapine may have contributed to the cause of death.
Conclusions

